What is Claimed:


1. A compound comprising a single stranded modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 16 to 30 linked nucleosides and has a nucleobase sequence comprising any one of SEQ ID NOs: 455, 237, 448, 453, 444, 450, 598, 198, 549 and 228 wherein the modified oligonucleotide has:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nuclesides;

and a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar; wherein the conjugate group comprises:



and wherein the compound is capable of inhibiting Complement Factor B (CFB) expression.

2. The compound of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 455, 237, 453, 444, 448, 450, 198 or 228 wherein the modified oligonucleotide has:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides; and

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing

segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage and wherein each cytosine is a 5-methylcytosine.

3. The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 598, wherein the modified oligonucleotide has:

a gap segment consisting of ten linked deoxynucleosides;

a 5’ wing segment consisting of three linked nucleosides; and

a 3’ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment; wherein the 5’ wing segment comprises a 2’-O-methoxyethyl sugar, 2’-O-methoxyethyl sugar and cEt sugar in the 5’ to 3’ direction; wherein the 3’ wing segment comprises a cEt sugar, cEt sugar, and 2’-O-methoxyethyl sugar in the 5’ to 3’ direction; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

4. The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides and has a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 549, wherein the modified oligonucleotide has:

a gap segment consisting of ten linked deoxynucleosides;

a 5’ wing segment consisting of three linked nucleosides; and

a 3’ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment; wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

5. The compound of claim 1, wherein the oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to SEQ ID NO: 1 or 2.

6. The compound of claim 1 or claim 5, wherein the modified sugar is a bicyclic sugar, optionally wherein the bicyclic sugar is selected from the group consisting of: 4'-(CH2)-O-2' (LNA); 4'-(CH2) 2-O-2' (ENA); and 4'-CH(CH3)-O-2' (cEt).

7. The compound of any one of claims 1, 5 or 6, wherein the modified sugar is a 2’-O-

methoxyethyl.

8. The compound of claim 1, or any one of claims 5 – 7, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage or at least one modified nucleobase.

9. The compound of claim 8, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage or, wherein each internucleoside linkage of the modified oligonucleotide comprises a phosphorothioate internucleoside linkage.

10. The compound of claim 8 or claim 9, wherein the modified nucleobase is a 5-methylcytosine.

11. The compound of any one of claims 1 – 10, wherein the conjugate group is linked to the modified oligonucleotide:

(i) at the 5’ end of the modified oligonucleotide; or

(ii) at the 3’ end of the modified oligonucleotide.

12. A composition comprising the compound of any one of claims 1-11 or a salt thereof and at least one of a pharmaceutically acceptable carrier or diluent.

13. A compound according to any one of claims 1-11 or a composition according to claim 12 for use as a medicament.

14. Use of a compound according to any one of claims 1-11 or a composition according to claim 12 in the manufacture of a medicament for the treatment of a disease associated with dysregulation of the complement alternative pathway in a subject.

15. The use of claim 14 wherein the disease is macular degeneration, age related macular degeneration (AMD), wet AMD, dry AMD or Geographic Atrophy.

16. The use of claim 14 wherein the disease is a kidney disease.

17. The use of claim 16 wherein the kidney disease is lupus nephritis, systemic lupus erythematosus (SLE), dense deposit disease (DDD), C3 glomerulonephritis (C3GN), CFHR5 nephropathy or atypical hemolytic uremic syndrome (aHUS).